- Home
- MGLD vs IMAB Comparison
MGLD vs IMAB Comparison
Compare MGLD & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- IMAB
- Stock Information
- Founded
- MGLD 1996
- IMAB 2014
- Country
- MGLD United States
- IMAB United States
- Employees
- MGLD N/A
- IMAB N/A
- Industry
- MGLD Finance/Investors Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- IMAB Health Care
- Exchange
- MGLD Nasdaq
- IMAB Nasdaq
- Market Cap
- MGLD 80.3M
- IMAB 83.8M
- IPO Year
- MGLD N/A
- IMAB 2020
- Fundamental
- Price
- MGLD $1.71
- IMAB $1.07
- Analyst Decision
- MGLD
- IMAB Strong Buy
- Analyst Count
- MGLD 0
- IMAB 3
- Target Price
- MGLD N/A
- IMAB $8.00
- AVG Volume (30 Days)
- MGLD 24.6K
- IMAB 682.1K
- Earning Date
- MGLD 02-12-2025
- IMAB 03-13-2025
- Dividend Yield
- MGLD N/A
- IMAB N/A
- EPS Growth
- MGLD N/A
- IMAB N/A
- EPS
- MGLD N/A
- IMAB N/A
- Revenue
- MGLD $32,511,000.00
- IMAB $3,313,984.00
- Revenue This Year
- MGLD N/A
- IMAB N/A
- Revenue Next Year
- MGLD N/A
- IMAB N/A
- P/E Ratio
- MGLD N/A
- IMAB N/A
- Revenue Growth
- MGLD N/A
- IMAB N/A
- 52 Week Low
- MGLD $0.78
- IMAB $0.84
- 52 Week High
- MGLD $2.10
- IMAB $2.08
- Technical
- Relative Strength Index (RSI)
- MGLD 51.19
- IMAB 55.17
- Support Level
- MGLD $1.64
- IMAB $1.00
- Resistance Level
- MGLD $1.99
- IMAB $1.20
- Average True Range (ATR)
- MGLD 0.20
- IMAB 0.12
- MACD
- MGLD -0.02
- IMAB 0.02
- Stochastic Oscillator
- MGLD 23.68
- IMAB 40.97
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).